Physician profile
Jerri Bradshaw
NPI 1609893676
$3,765.50
in general payments reported to CMS, 2019-2025
28 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $379 · 2022: $1,182 · 2023: $1,007 · 2024: $896 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $565.34 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $479.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $474.96 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $442.93 | 2021-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $418.62 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $335.70 | 2021-2025 | |
| Insulet Corporation | $234.22 | 2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $163.63 | 2021-2024 | Keveyis |
| Abbvie INC. | $118.57 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.65 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $55.18 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $44.96 | 2023 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $42.14 | 2021-2024 | Spravato |
| Dexcom, INC. | $36.53 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $29.49 | 2023 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $20.12 | 2024 | Trintellix |
| Mylan Specialty L.P. | $19.82 | 2024 | Yupelri |
| Antares Pharma, INC. | $18.69 | 2023 | Tlando, Xyosted, Nocdurna |
| Sumitomo Pharma America, INC. | $17.65 | 2024 | Gemtesa |
| Astellas Pharma US INC | $17.63 | 2021 | |
| Halozyme INC | $16.06 | 2023 | |
| Novartis Pharmaceuticals Corporation | $15.45 | 2023 | |
| Abbott Laboratories | $15.08 | 2023 | Freestyle Libre 3 |
| Nabriva Therapeutics, Plc | $15.03 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.97 | 2023 | Ajovy |
| Genentech USA, INC. | $14.46 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.00 | 2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerri Bradshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.